PMV Pharmaceuticals公布了其药物Rezatapopt单一疗法在Pynnacle 2期试验中的积极中期数据,该试验针对携带TP53 Y220C突变的多种实体瘤患者。
PMV Pharmaceuticals公布了其药物Rezatapopt单一疗法在Pynnacle 2期试验中的积极中期数据,该试验针对携带TP53 Y220C突变的多种实体瘤患者。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.